Plasma Cathepsin L and Its Related Pro/Antiangiogenic Factors Play Useful Roles in Predicting Rich Coronary Collaterals in Patients with Coronary Heart Disease
Free accessResearch articleFirst published online August, 2010
Plasma Cathepsin L and Its Related Pro/Antiangiogenic Factors Play Useful Roles in Predicting Rich Coronary Collaterals in Patients with Coronary Heart Disease
Cathepsin L enhances angiogenesis by increasing extracellular matrix degradation and remodelling. This study investigated whether plasma cathepsin L could be used as a biomarker to predict collateral formation in patients with coronary heart disease (CHD). Patients with CHD (n = 218; aged 67 ± 11 years) underwent coronary angiography and were categorized as having either ‘poor’ or ‘rich’ collaterals. Plasma cathepsin L, the proangiogenic placenta growth factor (PLGF) and the antiangiogenic factors, cystatin C and endostatin, were measured. Elevated cathepsin L and PLGF levels were independently and significantly associated with enhanced collateral formation in patients with CHD; subgroup analyses also showed a significant correlation in patients with diabetes and acute coronary syndrome. Plasma endostatin and cystatin C levels were not significantly correlated with coronary collateral formation. Plasma cathepsin L and PLGF, acting as important modulators of angiogenesis, could be used as biomarkers to predict coronary collateral formation in patients with CHD.
UrbichCHeeschenCAicherA: Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med2005; 11: 206–213.
3.
ShiGPSukhovaGKKuzuyaM: Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res2003; 92: 493–500.
4.
StypmannJGläserKRothW: Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA2002; 99: 6234–6239.
5.
TobinDJFoitzikKReinheckelT: The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am J Pathol2002; 160: 1807–1821.
6.
FelborUDreierLBryantRA: Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J2000; 19: 1187–1194.
7.
KimYMHwangSKimYM: Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem2002; 277: 27872–27879.
8.
RehnMVeikkolaTKukk-ValdreE: Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA2001; 98: 1024–1029.
9.
ShichiriMHirataY: Antiangiogenesis signals by endostatin. FASEB J2001; 15: 1044–1053.
10.
HarringtonLSSainsonRCWilliamsCK: Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res2008; 75: 144–154.
11.
DiSalvoJBayneMLConnG: Purification and characterization of a naturally occurring vascular endothelial growth factor · placenta growth factor heterodimer. J Biol Chem 1995; 270: 7717–7723.
12.
MatteiMGBorgJPRosnetO: Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. Genomics1996; 32: 168–169.
13.
AutieroMLuttunATjwaM: Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost2003; 1: 1356–1370.
14.
LuttunATjwaMMoonsL: Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med2002; 8: 831–840.
15.
SodhaNRClementsRTBoodhwaniM: Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol2009; 296: H428–H434.
16.
LiuYLiXPengD: Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. Am J Cardiol2009; 103: 476–481.
17.
AbaciAOguzhanAKahramanS: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation1999; 99: 2239–2242.
18.
WeihrauchDLohrNLMraovicB: Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin. Circulation2004; 109: 2343–2348.
19.
LeveyASBoschJPLewisJBfor the Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med1999; 130: 461–470.
20.
National Cholesterol Education Program Expert Panel: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Bethesda: National Institutes of Health, 2002 (available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf).
21.
RentropKPThorntonJCFeitF: Determinants and protective potential of coronary arterial collaterals as assessed by an angioplasty model. Am J Cardiol1988; 61: 677–684.
22.
RentropKPCohenMBlankeH: Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol1985; 5: 587–592.
23.
KocamanSAArslanUTavilY: Increased circulating monocyte count is related to good collateral development in coronary artery disease. Atherosclerosis2008; 197: 753–756.
24.
SchiffrinELLipmanMLMannJF: Chronic kidney disease: Effects on the cardiovascular system. Circulation2007; 116: 85–97.
25.
LiuJSukhovaGKYangJT: Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis2006; 184: 302–311.
26.
MaciewiczRAWottonSFEtheringtonDJ: Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS Lett1990; 269: 189–193.
27.
AsaharaTMuroharaTSullivanA: Isolation of putative progenitor endothelial cells for angiogenesis. Science1997; 275: 964–967.
28.
KhuranaRSimonsMMartinJF: Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation2005; 112: 1813–1824.
29.
LiuJMaLYangJ: Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis2006; 186: 411–419.
30.
LiWKornmarkLJonassonL: Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis2009; 202: 92–102.
31.
MookORFrederiksWMVan NoordenCJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta2004; 1705: 69–89.
32.
PepperMS: Extracellular proteolysis and angiogenesis. Thromb Haemost2001; 86: 346–355.
FolkmanJ: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med1995; 1: 27–31.
35.
YanamandraNGumidyalaKVWaldronKG: Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene2004; 23: 2224–2230.
36.
LakkaSSGondiCSYanamandraN: Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene2004; 23: 4681–4689.
37.
GondiCSLakkaSSDinhDH: RNAimediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene2004; 23: 8486–8496.
38.
KamphausGDColoradoPCPankaDJ: Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem2000; 275: 1209–1215.
39.
MaeshimaYYerramallaULDhanabalM: Extracellular matrix-derived peptide binds to αvβ3 integrin and inhibits angiogenesis. J Biol Chem2001; 276: 31959–31968.
40.
HeGALuoJXZhangTY: Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. Biochem Biophys Res Commun2003; 312: 801–805.
41.
O'ReillyMSBoehmTShingY: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell1997; 88: 277–285.
AbdollahiAHlatkyLHuberPE: Endostatin: The logic of antiangiogenic therapy. Drug Resist Updat2005; 8: 59–74.
44.
ColletteJUlkuASDerCJ: Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int J Cancer2004; 112: 190–199.
